Dotmatics builds R&D scientific software for life sciences organisations, connecting laboratory data, analysis and decision-making across the research and development workflow. Founded in 2005 by two scientists from Merck Pharmaceuticals, the company employs more than 800 people and serves over 2 million scientists and 10,000 scientific R&D enterprise customers in more than 180 countries. In 2025 it was acquired by Siemens AG for $5.1 billion and now sits within the Siemens Xcelerator portfolio.
Its technology spans cloud-based scientific software, AI-powered scientific intelligence, bioinformatics and cheminformatics, electronic lab notebooks, flow cytometry analysis, proteomics, data visualisation, workflow automation, multimodal data management and concepts such as the digital thread and digital twins. Luma, its AI-powered Scientific Intelligence Platform, handles data management and workflow automation for multimodal scientific discovery. The Dotmatics enterprise data platform unifies the wider application portfolio, which includes GraphPad Prism, Geneious, SnapGene, FCS Express and OMIQ, and spans early-stage research through clinical development.
The company operates across life sciences, pharmaceuticals, drug development, biologics, chemistry, materials science, preclinical research, clinical development and mRNA development. It describes its work as building a ‘Lab of the Future’, applying science, data and AI to accelerate discovery and shorten the path to market for new medicines.
